MedTrace Logo

SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT

NCT04387695 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2023-02-16

No results posted yet for this study

Summary

To evaluate and compare the efficacy and safety of SBRT sequential TACE combined with sorafenib versus sorafenib alone in the treatment of unreactable HCC with PVTT.

Conditions

Interventions

RADIATION

SBRT+TACE+Sorafenib

SBRT first for the PVTT +TACE for HCC within a week next +Sorafenib with 2 weeks later

DRUG

Sorafenib

Sorafenib 800 mg/day orally

Sponsors & Collaborators

  • First Affiliated Hospital of Zhejiang University

    lead OTHER

Principal Investigators

  • Jun-hui Sun, MD,PH.D · First Affiliated Hospital of Zhejiang University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-30
Primary Completion
2023-08-01
Completion
2023-08-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04387695 on ClinicalTrials.gov